Heather Giles
Chief Executive Officer at Vapogenix, Inc.
Profile
Heather Giles is currently the President, CEO & Director at Vapogenix, Inc. She is also a Director at RNIB Charity and a Member of the British Pharmacological Society.
Previously, she worked as the International Disease Strategy Director at GSK Plc.
From 2001 to 2011, she served as the Vice President-Strategic Planning at Encysive Pharmaceuticals, Inc. Prior to that, she was the Head-Receptor Pharmacology at GlaxoWellcome from 1995 to 2000.
Additionally, she worked as a Principal at Inverseon, Inc. Dr. Giles holds a doctorate degree from the University of Oxford and an undergraduate degree from the University of London.
Heather Giles active positions
Companies | Position | Start |
---|---|---|
Vapogenix, Inc.
Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Chief Executive Officer | 2017-06-30 |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Corporate Officer/Principal | - |
RNIB Charity
RNIB Charity Miscellaneous Commercial ServicesCommercial Services RNIB Charity is a non-profit charitable organization that provides support and advice to people with sight problems. The non-profit company is based in London, UK. The British company was founded in 2014. | Director/Board Member | 2019-05-01 |
Former positions of Heather Giles
Companies | Position | End |
---|---|---|
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Corporate Officer/Principal | 2012-08-31 |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Corporate Officer/Principal | 2011-04-28 |
GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | 1999-12-31 |
GSK PLC | Corporate Officer/Principal | - |
Training of Heather Giles
University of Oxford | Doctorate Degree |
University of London | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GSK PLC | Health Technology |
Private companies | 6 |
---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
Vapogenix, Inc.
Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Health Services |
GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Health Technology |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Miscellaneous |
RNIB Charity
RNIB Charity Miscellaneous Commercial ServicesCommercial Services RNIB Charity is a non-profit charitable organization that provides support and advice to people with sight problems. The non-profit company is based in London, UK. The British company was founded in 2014. | Commercial Services |
- Stock Market
- Insiders
- Heather Giles